MCID: HRP004
MIFTS: 60

Herpes Zoster

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Herpes Zoster

MalaCards integrated aliases for Herpes Zoster:

Name: Herpes Zoster 12 74 25 53 54 43 15 17
Shingles 12 74 25 53 42 3 62
Herpes Zoster Disease 71
Herpes Zona 12
Zoster 25

Classifications:



External Ids:

Disease Ontology 12 DOID:8536
ICD9CM 34 053
MeSH 43 D006562
NCIt 49 C71079
SNOMED-CT 67 4740000
UMLS 71 C0019360

Summaries for Herpes Zoster

MedlinePlus : 42 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What other problems can shingles cause? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary : Herpes Zoster, also known as shingles, is related to postherpetic neuralgia and chickenpox, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is FCGR3A (Fc Fragment Of IgG Receptor IIIa), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Foscarnet and Capsaicin have been mentioned in the context of this disorder. Affiliated tissues include nerve fiber, skin and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

Genetics Home Reference : 25 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50. Shingles is characterized by a severely painful, itchy, or tingling rash, most commonly on one side of the torso, although it can occur anywhere on the body. Reactivation of the virus usually occurs in a single nerve, leading to the symptoms of shingles in just the region of skin connected to that nerve. When the nerve connected to the eye and the skin surrounding it is affected, the condition is called herpes zoster ophthalmicus. This form of shingles, which accounts for about 20 percent of cases, can cause permanent vision impairment. Some individuals with shingles feel throbbing or tingling in the affected region shortly before the rash appears. Blisters form in the rash area, break open, and scab over in a few days. Healing usually takes 2 to 4 weeks. Most people have only one episode of shingles, although it can recur in rare cases. In 5 to 20 percent of people with shingles, severe pain continues in the affected region after healing of the rash, which is known as postherpetic neuralgia (PHN). PHN is the most common complication of shingles. It can also involve severe itchiness or an overactive pain response to things that do not usually cause pain (allodynia), such as a light touch. PHN can last weeks, months, or even years. The likelihood of developing PHN after shingles and its severity increase with age. The pain caused by shingles and PHN can disrupt day-to-day activities and reduce a person's quality of life.

CDC : 3 Shingles is a painful rash that usually develops on one side of the body, often the face or torso. The rash consists of blisters that typically scab over in 7 to 10 days and clears up within 2 to 4 weeks. Some people describe the pain as an intense burning sensation. For some people, the pain can last for months or even years after the rash goes away. This long-lasting pain is called postherpetic neuralgia (PHN), and it is the most common complication of shingles. Your risk of getting shingles and PHN increases as you get older. Two vaccines are licensed and recommended to prevent shingles in the U.S.. Zoster vaccine live (ZVL, Zostavax) has been in use since 2006. Recombinant zoster vaccine (RZV, Shingrix), has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine

NINDS : 53 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 62 About shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body. People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox. Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications. Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

Wikipedia : 74 Shingles, also known as zoster or herpes zoster, is a viral disease characterized by a painful skin rash... more...

Related Diseases for Herpes Zoster

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1125)
# Related Disease Score Top Affiliating Genes
1 postherpetic neuralgia 33.9 HLA-DRB1 HLA-B HLA-A
2 chickenpox 32.3 IL2 IL10 IFNG GYPC CD8A
3 exanthem 32.2 PDCD1 IL2 IL10 CD8A
4 keratitis, hereditary 31.9 TLR2 IL10 CD8A
5 neuritis 31.5 IL10 IFNG CCR5 APOE
6 herpes simplex 31.4 TLR2 IFNA1 HLA-B GYPC CD8A
7 meningitis 31.4 TLR2 IL2 IL10 IFNG HLA-B
8 optic neuritis 31.3 IL10 HLA-DRB1 CCR5
9 spondylitis 31.2 IL10 IFNG HLA-B
10 conjunctivitis 31.2 IL2 IL10 IFNG HLA-B
11 lupus erythematosus 31.2 PDCD1 IL10 IFNG HLA-DRB1 FCGR3A
12 myositis 31.2 IL2 IFNG HLA-DRB1 HLA-B
13 dermatitis 31.1 TLR2 IL2 IL10 IFNG
14 uveitis 31.1 IL2 IL10 IFNG IFNA2 HLA-B HLA-A
15 pemphigus 31.0 IL10 HLA-DRB1 COL17A1
16 cellulitis 31.0 IL10 COL17A1 CD8A
17 temporal arteritis 31.0 IFNG HLA-DRB1 CD8A
18 myeloma, multiple 31.0 IL2 IL10 IFNG IFNA1 FCGR3A CD8A
19 chronic graft versus host disease 31.0 IL10 IFNG
20 allergic hypersensitivity disease 30.9 TLR2 IL2 IL10 IFNG
21 ulcerative colitis 30.9 IL2 IL10 IFNG HLA-DRB1
22 cutaneous lupus erythematosus 30.9 IL10 IFNG IFNA1
23 syphilis 30.9 HLA-DRB1 CD8A CCR5
24 lichen planus 30.9 IL2 IL10 IFNG COL17A1
25 neutropenia 30.9 IFNA2 IFNA1 FCGR3A DPYD
26 immune deficiency disease 30.9 IL2 IL10 IFNG IFNA1 HLA-B HLA-A
27 mumps 30.9 IL2 IL10 IFNG IFNA1 HLA-DRB1
28 pityriasis rosea 30.8 HLA-DRB1 HLA-B HLA-A
29 contact dermatitis 30.8 TLR2 IL2 IL10 IFNG
30 osteomyelitis 30.8 TLR2 IL10 IFNG
31 mycosis fungoides 30.8 IL2 IFNG IFNA2 IFNA1
32 myocarditis 30.8 IL2 IL10 IFNG HLA-B
33 skin disease 30.8 TLR2 IL2 IL10 IFNG HLA-B COL17A1
34 combined t cell and b cell immunodeficiency 30.7 IL2 IL10 CD8A
35 leukemia, chronic lymphocytic 30.7 IL2 IL10 IFNA1 FCGR3A CD8A CCR5
36 genital herpes 30.7 TLR2 IL10 GYPC CD8A APOE
37 vaccinia 30.7 IL2 IFNA1 HLA-A CCR5
38 discoid lupus erythematosus 30.7 IL10 IFNA2 IFNA1 HLA-DRB1
39 rubella 30.7 IL2 IL10 IFNG HLA-DRB1 HLA-B HLA-A
40 pulmonary tuberculosis 30.7 TLR2 IL2 IL10 IFNG HLA-DRB1
41 crohn's disease 30.7 TLR2 IL2 IL10 IFNG HLA-DRB1
42 toxic shock syndrome 30.6 TLR2 IL2 IL10 IFNG
43 human immunodeficiency virus type 1 30.6 IL2 IL10 IFNG IFNA1 HLA-B HLA-A
44 cutaneous t cell lymphoma 30.6 IL2 IFNG IFNA2 IFNA1
45 candidiasis 30.6 TLR2 IL2 IL10 IFNG
46 eye disease 30.6 TLR2 IL2 IL10 IFNG CD8A
47 sarcoidosis 1 30.6 IL2 IFNG HLA-DRB1 HLA-A CD8A CCR5
48 graft-versus-host disease 30.6 IL2 IL10 IFNG HLA-DRB1 HLA-B HLA-A
49 measles 30.6 TLR2 IL2 IFNG IFNA1 HLA-DRB1 HLA-A
50 tetanus 30.6 IL2 IL10 IFNG HLA-A

Graphical network of the top 20 diseases related to Herpes Zoster:



Diseases related to Herpes Zoster

Symptoms & Phenotypes for Herpes Zoster

Symptoms:

12
  • fever
  • paresthesia
  • headache
  • malaise
  • itching
  • rash which is followed by blisters
  • burning pain

UMLS symptoms related to Herpes Zoster:


seizures, tremor, fever, angina pectoris, pruritus, back pain, pain, headache, syncope, chronic pain, sciatica, exanthema, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Herpes Zoster according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.83 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.83 IFNA1 IFNA2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.83 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.83 IFNA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.83 HLA-A HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.83 IFNA2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.83 IFNA1 IFNA2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.83 HLA-A HLA-B IFNA1 IFNA2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.83 HLA-A HLA-B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.83 IFNA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.83 IFNA2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.83 IFNA2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.83 HLA-A HLA-B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.83 IFNA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.83 HLA-A HLA-B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 IFNA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.83 HLA-A HLA-B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.83 IFNA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.83 IFNA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.83 IFNA1

MGI Mouse Phenotypes related to Herpes Zoster:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.61 APOE CCR5 DHFR IFNG IL10 IL2
2 neoplasm MP:0002006 9.17 CCR5 IFNG IL10 IL2 PDCD1 TLR2

Drugs & Therapeutics for Herpes Zoster

PubMed Health treatment related to Herpes Zoster: 62

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin ). Prescription painkillers are sometimes used to relieve more severe pain. Thorough skin care is recommended if you have shingles . Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters . Most of them contain tanins, zinc , menthol or polidocanol . If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work. Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system , if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy ." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion ). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
2
Capsaicin Approved Phase 4 404-86-4 1548943
3
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
4
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
5
Budesonide Approved Phase 4 51333-22-3 63006 5281004
6
leucovorin Approved Phase 4 58-05-9 6006 143
7
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
8
Interferon beta-1b Approved Phase 4 145155-23-3
9
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
10
Tofacitinib Approved, Investigational Phase 4 477600-75-2
11 Vedolizumab Approved Phase 4 943609-66-3
12
Certolizumab pegol Approved Phase 4 428863-50-7
13
Mercaptopurine Approved Phase 4 50-44-2 667490
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Adalimumab Approved Phase 4 331731-18-1 16219006
16
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
21 Reverse Transcriptase Inhibitors Phase 4
22 Dermatologic Agents Phase 4
23 Antipruritics Phase 4
24 Cyclooxygenase 2 Inhibitors Phase 4
25 Respiratory System Agents Phase 4
26 calcium channel blockers Phase 4
27 Calcium, Dietary Phase 4
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
29 Anti-Asthmatic Agents Phase 4
30 Bronchodilator Agents Phase 4
31 Folic Acid Antagonists Phase 4
32 Vitamin B Complex Phase 4
33 Vitamin B9 Phase 4
34 Folate Phase 4
35 Fingolimod Hydrochloride Phase 4
36 MF59 oil emulsion Phase 4
37 (T,G)-A-L Phase 4
38 Interferon-beta Phase 4
39 interferons Phase 4
40
Glatiramer Acetate Phase 4 147245-92-9 3081884
41 Anesthetics, Local Phase 4
42 polysaccharide-K Phase 4
43 Mesalamine Phase 4 89-57-6
44 Protein Kinase Inhibitors Phase 4
45 Janus Kinase Inhibitors Phase 4
46
Methylene blue Approved, Investigational Phase 3 61-73-4
47
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
48
Remifentanil Approved Phase 3 132875-61-7 60815
49
Methadone Approved Phase 3 76-99-3 4095
50
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 377)
# Name Status NCT ID Phase Drugs
1 A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
2 Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations Unknown status NCT00940940 Phase 4
3 A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya. Unknown status NCT02514018 Phase 4
4 Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
5 Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
6 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
7 An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
8 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
9 T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape Completed NCT01911065 Phase 4
10 Immune Response to Shingles Vaccination Completed NCT02624375 Phase 4 Zoster Vaccine Live
11 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
12 Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia Completed NCT00885586 Phase 4 gabapentine
13 An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea Completed NCT01556451 Phase 4
14 A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age Completed NCT00550745 Phase 4
15 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
16 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
17 An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old. Completed NCT00681031 Phase 4
18 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
19 Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
20 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
21 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
22 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
23 A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
24 Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina Completed NCT00830648 Phase 4
25 Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
26 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Completed NCT03330171 Phase 4
27 A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
28 A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Completed NCT02187055 Phase 4 Tofacitinib with methotrexate;Tofacitinib without methotrexate
29 Live Attenuated Varicella Vaccine: A New Effective Adjuvant Weapon in the Battlefield Against Severe Resistant Psoriasis, a Randomized Controlled Trial Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
30 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
31 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
32 A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
33 Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
34 Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation Recruiting NCT03016884 Phase 4
35 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
36 Safety and Immunogenicity of Recombinant Glycoprotein E Herpes Zoster Subunit (HZ/su) Vaccine in Renal Transplant Recipients Recruiting NCT03993717 Phase 4
37 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia and for the Prevention of Post Herpetic Neuralgia- a Randomized Controlled Trial Recruiting NCT03809702 Phase 4 Pregabalin;Placebo
38 The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting NCT03591770 Phase 4
39 Does Stellate Ganglion Blockade (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes? A Pilot Prospective Cohort Study Recruiting NCT03796195 Phase 4 .5% Bupivacaine
40 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Active, not recruiting NCT03493776 Phase 4
41 A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Active, not recruiting NCT02444936 Phase 4 ZOSTAVAX
42 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study) Active, not recruiting NCT02868970 Phase 4
43 The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER) Not yet recruiting NCT03886038 Phase 4
44 Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine Not yet recruiting NCT02026089 Phase 4
45 A Double Blind Placebo-controlled Randomized Study of Varicella Zoster Vaccine in Patients With Moderate-to-severe Plaque Psoriasis Who Are Candidates for Biologic Therapy Terminated NCT02408159 Phase 4 Varicella Zoster Vaccine;Placebo
46 A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections Unknown status NCT03178747 Phase 3
47 Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation Unknown status NCT00213304 Phase 3
48 Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland Unknown status NCT00492739 Phase 2, Phase 3
49 Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery Unknown status NCT00926419 Phase 2, Phase 3
50 Thoracic Epidural Morphine Versus Triamcinolone Acetonide Analgesia in Flail Chest Unknown status NCT03413059 Phase 2, Phase 3 Morphine Sulfate;Triamcinolone Acetonide

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acyclovir
Acyclovir Sodium
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
famciclovir
Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
valacyclovir
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes zoster

Genetic Tests for Herpes Zoster

Anatomical Context for Herpes Zoster

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Zoster:

19
Nerve Fiber

MalaCards organs/tissues related to Herpes Zoster:

40
Skin, T Cells, Eye, Bone, Testes, Kidney, Liver

Publications for Herpes Zoster

Articles related to Herpes Zoster:

(show top 50) (show all 9579)
# Title Authors PMID Year
1
The Relationship Between Herpes Zoster, Syphilis and Chickenpox. 61 42
31688874 2019
2
The risk of herpes zoster virus infection in patients with depression: A longitudinal follow-up study using a national sample cohort. 61 42
31577760 2019
3
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. 61 42
31287523 2019
4
Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. 54 61
14593495 2005
5
Chronic varicella-zoster virus skin lesions in patients with human immunodeficiency virus are related to decreased expression of gE and gB. 54 61
9207378 1997
6
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. 54 61
9164418 1997
7
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 54 61
1569421 1992
8
[Therapeutic indications in herpes zoster]. 54 61
1828198 1991
9
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2020
10
Anti-inflammatory mechanism and active ingredients of the Chinese tallow tree. 61
31870794 2020
11
Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life. 61
31605822 2020
12
Behçet's Disease with Severe Autonomic Disorders Developing after Herpes Zoster. 61
32009095 2020
13
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. 61
31312844 2020
14
Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections. 61
31995350 2020
15
An Unusual Case of Modified Lemierre's Syndrome Caused by Staphylococcus aureus Cellulitis. 61
32008035 2020
16
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. 61
32033941 2020
17
Genital herpes zoster in an immunocompetent child. 61
32031528 2020
18
Herpes zoster after recombinant zoster vaccine: A first case report. 61
31377436 2020
19
Herpes Zoster Subunit Vaccination for Renal Transplant Recipients. 61
31504313 2020
20
Ultraviolet Radiation Exposure and the Risk of Herpes Zoster in Three Prospective Cohort Studies. 61
31883695 2020
21
Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review. 61
31741185 2020
22
Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. 61
31049925 2020
23
Vaccine-Strain Herpes Zoster Ophthalmicus in a 14-month-old Boy Prompting an Immunodeficiency Workup: Case Report and Review of Vaccine-strain Herpes Zoster. 61
31929435 2020
24
Genital zoster in near term pregnancy: Case report and need of management guidelines. 61
31852623 2020
25
Knowledge about vaccines and vaccination in older people: Results of a national survey by the Italian Society for Gerontology & Geriatrics. 61
31822428 2020
26
Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. 61
31599852 2020
27
Short-Term Systemic Corticosteroids: Appropriate Use in Primary Care. 61
31939645 2020
28
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. 61
32006348 2020
29
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. 61
31964419 2020
30
Higher risk of herpes zoster in stroke patients. 61
32017810 2020
31
Varicella-zoster meningitis in an immunocompetent young man presenting with a painless erythematous rash. 61
31969416 2020
32
Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. 61
32001495 2020
33
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 61
31413005 2020
34
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. 61
31660640 2020
35
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. 61
30784354 2020
36
Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. 61
31953880 2020
37
Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain? 61
31679866 2020
38
Delayed Initiation of Supplemental Pain Management is Associated with Postherpetic Neuralgia: A Retrospective Study. 61
32013280 2020
39
Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease. 61
31897892 2020
40
Vaccination Programs for Adults in Europe, 2019. 61
31968652 2020
41
Multidermatomal Herpes Zoster in immunocompromised patient. 61
31422652 2020
42
Erectile Dysfunction Secondary to Herpes Zoster. 61
32001867 2020
43
Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials. 61
31729189 2020
44
[Bullous pemphigoid on a healed herpes zoster : A rare example of an isotopic response]. 61
31236629 2020
45
Adult black dot tinea capitis caused by Trichophyton tonsurans complicated with herpes zoster. 61
31923110 2020
46
Risk Factors for Herpes Zoster Infection: A Meta-Analysis. 61
32010734 2020
47
Herpes zoster duplex in a patient with influenza A and bacterial superinfection. 61
31541479 2020
48
Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study. 61
30570833 2020
49
Polymerase chain reaction for the diagnosis of herpesvirus infections in dermatology : Analysis of clinical data. 61
31820101 2020
50
Varicella-zoster virus infection in children with autologous hematopoietic cell transplantation: A retrospective, single-center study in Korea. 61
31962166 2020

Variations for Herpes Zoster

Expression for Herpes Zoster

Search GEO for disease gene expression data for Herpes Zoster.

Pathways for Herpes Zoster

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TLR2 PDCD1 IL2 IL10 IFNG IFNA2
2
Show member pathways
13.36 IL2 IL10 IFNG IFNA2 IFNA1 HLA-DRB1
3
Show member pathways
13.08 TLR2 IL2 IL10 IFNG IFNA2 IFNA1
4
Show member pathways
12.97 TLR2 IL2 IFNA2 IFNA1 HLA-B HLA-A
5
Show member pathways
12.93 TLR2 IFNA2 IFNA1 HLA-B HLA-A CCR5
6 12.77 TLR2 IFNG IFNA2 IFNA1 HLA-DRB1 HLA-B
7
Show member pathways
12.68 TLR2 IL2 IFNG IFNA2 IFNA1 HLA-DRB1
8
Show member pathways
12.59 TLR2 IL2 IL10 IFNG HLA-DRB1
9
Show member pathways
12.56 TLR2 PDCD1 IL2 IL10 IFNG CD8A
10
Show member pathways
12.54 IFNG IFNA2 IFNA1 HLA-DRB1 HLA-B HLA-A
11 12.49 TLR2 PDCD1 IL2 IL10 IFNG IFNA1
12
Show member pathways
12.35 IL2 IL10 IFNG IFNA2 IFNA1
13
Show member pathways
12.35 IL2 IL10 IFNG IFNA2 IFNA1 HLA-DRB1
14
Show member pathways
12.34 IL2 IFNG IFNA2 IFNA1 HLA-B HLA-A
15 12.31 IL2 HLA-DRB1 HLA-B HLA-A
16
Show member pathways
12.3 IL2 IFNG DHFR APOE
17
Show member pathways
12.25 TLR2 IL10 IFNG HLA-DRB1 FCGR3A CCR5
18
Show member pathways
12.21 IL2 IL10 IFNG IFNA2 IFNA1 HLA-B
19 12.16 TLR2 HLA-DRB1 HLA-B HLA-A FCGR3A
20 12.12 PDCD1 HLA-DRB1 HLA-B HLA-A CD8A
21 12.08 HLA-B HLA-A FCGR3A CD8A
22
Show member pathways
12.05 TLR2 IL2 IL10 IFNG
23 11.99 IL2 IL10 IFNG IFNA2 CD8A
24 11.84 IL10 HLA-DRB1 FCGR3A
25 11.82 TLR2 IFNG HLA-DRB1
26 11.82 IL2 IL10 IFNG CD8A
27 11.76 IL2 IL10 IFNG FCGR3A
28
Show member pathways
11.69 IL2 IFNG HLA-DRB1 HLA-A CD8A CCR5
29 11.68 IL2 IL10 IFNG IFNA2 IFNA1 CCR5
30
Show member pathways
11.67 IL2 IFNG HLA-A CD8A
31 11.67 IL2 IL10 IFNG IFNA2 CD8A
32 11.55 TLR2 IL10 IFNG GYPC
33 11.5 IL2 IL10 IFNG
34 11.42 TLR2 IL10 IFNG IFNA2 IFNA1 HLA-DRB1
35 11.39 IFNG IFNA2 HLA-B
36 11.3 PDCD1 IL2 CD8A
37 11.27 IL2 IL10 IFNG HLA-DRB1
38 11.25 IL2 IFNG HLA-DRB1
39 11.21 IL2 IL10 IFNG

GO Terms for Herpes Zoster

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.01 IL2 IL10 IFNG IFNA2 IFNA1 HLA-B
2 integral component of plasma membrane GO:0005887 9.76 TRPV1 TLR2 HLA-B HLA-A GYPC COL17A1
3 phagocytic vesicle membrane GO:0030670 9.5 TLR2 HLA-B HLA-A
4 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-DRB1 HLA-B HLA-A
5 MHC class I protein complex GO:0042612 9.37 HLA-B HLA-A
6 external side of plasma membrane GO:0009897 9.17 TRPV1 PDCD1 HLA-DRB1 HLA-B FCGR3A CD8A
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DRB1 HLA-B HLA-A

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 TRPV1 TLR2 IL10 IFNA2 CCR5
2 immune system process GO:0002376 9.95 TLR2 PDCD1 IL2 HLA-DRB1 HLA-B HLA-A
3 cytokine-mediated signaling pathway GO:0019221 9.91 IL2 IL10 IFNA2 IFNA1 CCR5
4 cell surface receptor signaling pathway GO:0007166 9.88 TRPV1 IFNG IFNA2 CD8A CCR5
5 regulation of immune response GO:0050776 9.85 HLA-B HLA-A FCGR3A COL17A1 CD8A
6 B cell differentiation GO:0030183 9.76 IL10 IFNA2 IFNA1
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IL2 IFNG IFNA2
8 adaptive immune response GO:0002250 9.73 PDCD1 IL2 IFNG IFNA2 IFNA1 HLA-DRB1
9 B cell proliferation GO:0042100 9.7 IL10 IFNA2 IFNA1
10 microglial cell activation GO:0001774 9.67 TRPV1 TLR2 IFNG
11 interferon-gamma-mediated signaling pathway GO:0060333 9.67 IFNG HLA-DRB1 HLA-B HLA-A
12 type I interferon signaling pathway GO:0060337 9.62 IFNA2 IFNA1 HLA-B HLA-A
13 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.61 IFNG IFNA2 IFNA1
14 response to molecule of bacterial origin GO:0002237 9.59 TLR2 IL10
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IL10 IFNG
16 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.56 HLA-B HLA-A
17 protection from natural killer cell mediated cytotoxicity GO:0042270 9.54 HLA-B HLA-A
18 humoral immune response GO:0006959 9.46 PDCD1 IFNG IFNA2 IFNA1
19 immune response GO:0006955 9.32 TLR2 IL2 IL10 IFNG HLA-DRB1 HLA-B
20 antigen processing and presentation GO:0019882 9.26 HLA-DRB1 HLA-B HLA-A CD8A

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-B HLA-A
2 cytokine activity GO:0005125 9.02 IL2 IL10 IFNG IFNA2 IFNA1

Sources for Herpes Zoster

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....